Cost-effective production of a vaginal protein microbicide to prevent HIV transmission

@article{citeulike:2520222, abstract = {A series of small-molecule microbicides has been developed for vaginal delivery to prevent heterosexual HIV transmission, but results from human clinical trials have been disappointing. Protein-based microbicides, such as HIV-specific monoclonal antibodies, have been considered as an alternative approach. Despite their promising safety profile and efficacy, the major drawback of such molecules is the economy of large-scale production in mammalian cells, the current system of choice. Here, we show that an alternative biomanufacturing platform is now available for one of the most promising anti-HIV antibodies (2G12). Our data show that the HIV-neutralization capability of the antibody is equal to or superior to that of the same antibody produced in CHO cells. We conclude that this protein production system may provide a means to achieve microbicide ingredient manufacture at costs that would allow product introduction and manufacture in the developing world. 10.1073/pnas.0708841104}, author = {Ramessar, Koreen and Rademacher, Thomas and Sack, Markus and Stadlmann, Johannes and Platis, Dimitris and Stiegler, Gabriela and Labrou, Nikos and Altmann, Fritz and Ma, Julian and Stoger, Eva and Capell, Teresa and Christou, Paul }, citeulike-article-id = {2520222}, doi = {10.1073/pnas.0708841104}, journal = {Proceedings of the National Academy of Sciences}, keywords = {hiv, microbicide, molecular\_farming, pharmaplanta, pharming}, month = {March}, number = {10}, pages = {3727--3732}, posted-at = {2008-05-06 08:38:37}, priority = {2}, title = {Cost-effective production of a vaginal protein microbicide to prevent HIV transmission}, url = {http://dx.doi.org/10.1073/pnas.0708841104}, volume = {105}, year = {2008} }

TY - JOUR ID - citeulike:2520222 TI - Cost-effective production of a vaginal protein microbicide to prevent HIV transmission JF - Proceedings of the National Academy of Sciences VL - 105 IS - 10 SP - 3727 EP - 3732 N2 - A series of small-molecule microbicides has been developed for vaginal delivery to prevent heterosexual HIV transmission, but results from human clinical trials have been disappointing. Protein-based microbicides, such as HIV-specific monoclonal antibodies, have been considered as an alternative approach. Despite their promising safety profile and efficacy, the major drawback of such molecules is the economy of large-scale production in mammalian cells, the current system of choice. Here, we show that an alternative biomanufacturing platform is now available for one of the most promising anti-HIV antibodies (2G12). Our data show that the HIV-neutralization capability of the antibody is equal to or superior to that of the same antibody produced in CHO cells. We conclude that this protein production system may provide a means to achieve microbicide ingredient manufacture at costs that would allow product introduction and manufacture in the developing world. 10.1073/pnas.0708841104 KW - hiv KW - microbicide KW - molecular_farming KW - pharmaplanta KW - pharming AU - Ramessar, Koreen AU - Rademacher, Thomas AU - Sack, Markus AU - Stadlmann, Johannes AU - Platis, Dimitris AU - Stiegler, Gabriela AU - Labrou, Nikos AU - Altmann, Fritz AU - Ma, Julian AU - Stoger, Eva AU - Capell, Teresa AU - Christou, Paul PY - 2008/03/11/ UR - http://dx.doi.org/10.1073/pnas.0708841104 ER -